RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA
Delisted
RETA was delisted on the 25th of September, 2023.
80 hedge funds and large institutions have $240M invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2017 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 30 increasing their positions, 5 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $376K
Holders
80
Holding in Top 10
1
Calls
–
Puts
$376K
Top Buyers
| 1 | +$13.6M | |
| 2 | +$12.1M | |
| 3 | +$8.04M | |
| 4 |
Franklin Resources
San Mateo,
California
|
+$7.78M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.87M |
Top Sellers
| 1 | -$1.11M | |
| 2 | -$755K | |
| 3 | -$254K | |
| 4 |
JPMorgan Chase & Co
New York
|
-$123K |
| 5 |
CC
Capital Counsel
New York
|
-$117K |